Kailera Therapeutics Q3 2026 Results: Net Loss of $95.7M, Loss Widens
Kailera Therapeutics reported a net loss of $285.8 million for the nine months ended September 30, 2026, driven by a significant increase in research and development expenses to $256.6 million. During the period, the company completed its initial public offering, raising $662.0 million in net proceeds and ending the quarter with $1.03 billion in total stockholders' equity.
- Key figure
- Net loss $95.7M